Tasidotin
Alternative Names: BSF 223651; ILX 651; LU 223651; SYN-D; Synthadotin; Tasidotin HCl; Tasidotin hydrochlorideLatest Information Update: 04 Nov 2017
At a glance
- Originator Abbott Bioresearch Corporation
- Developer Genzyme Oncology; Sanofi Oncology
- Class Antineoplastics; Oligopeptides; Small molecules
- Mechanism of Action DNA topoisomerase inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Malignant melanoma; Solid tumours
- Discontinued Non-small cell lung cancer; Prostate cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Malignant-melanoma in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in USA (PO)
- 28 Apr 2011 Phase-I clinical trials in Malignant melanoma in USA (PO)